Sofie submits IND application for pancreatic PET agent

By staff writers

October 12, 2021 -- Molecular imaging developer Sofie Biosciences has submitted an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for a radiopharmaceutical targeting the fibroblast activation protein inhibitor (FAPI).

The IND is for a phase II, multicenter, single-blind, nonrandomized study of gallium-68 (Ga-68) FAPI-46 PET imaging in patients with pancreatic ductal adenocarcinoma, according to the vendor.

The filing enables select institutions to participate with Sofie in generating clinically relevant diagnostic imaging data to support ongoing work in pancreatic imaging, as well as efforts for other solid tumors and nononcologic applications, the company said.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking